pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-103b-1 |
Genomic Coordinates | chr5: 168560904 - 168560965 |
Description | Homo sapiens miR-103b-1 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-103b-2 |
Genomic Coordinates | chr20: 3917502 - 3917563 |
Description | Homo sapiens miR-103b-2 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-103b | |||||||||||||||||||||
Sequence | 1| UCAUAGCCCUGUACAAUGCUGCU |23 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | ChIP-seq | DRVs in miRNA |
|
|||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SREK1IP1 | ||||||||||||||||||||
Synonyms | P18SRP, SFRS12IP1 | ||||||||||||||||||||
Description | SREK1 interacting protein 1 | ||||||||||||||||||||
Transcript | NM_173829 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SREK1IP1 | |||||||||||||||||||||
3'UTR of SREK1IP1 (miRNA target sites are highlighted) |
>SREK1IP1|NM_173829|3'UTR 1 CTGAGACTTTGGCTTAAGCCGTTAAATTTAAAAATTTGTTTTTAAAACGTGTTTGCCCTTCCTTGGAATTTGCTATATAT 81 TATGCTTTGCAATAAATCACAGCCTTTTCCATATAGACATTTTTCGTATTTGGGACCATTATCCCTCTGGCAATATATTT 161 TTAATGTGCTGTAACTGTAAAGTATTAAATCAGTCTTGTTACTTGATAGCCATGCCCCAAGTATAGCTATTTGTGTATAC 241 TAAACACATCATTTTTGGTATTTGTGTCTCTGTGTGTTTGGCTAGTGTTACTACTTCATAAGTTCATTGTAAAATGGCTT 321 TACTGCCATCAACATGGGTCATCTACCTAGCAGTTAATGAGTATTGCTGGATCAGGTGTCCACCTTCCAATGATGAAGCA 401 AGGTAAGGGGTAATGTTTTGCTCTTGACACAGAGAAATTTAATAGCTTTATGTACTAAAATATAATATCTTTTAAAGATA 481 GTGAAATTCTTCAGTTTTTTAAATCTCTAGGGATTTTTTTTCAATGTTGTAGAAGATGCAGCTGCTTAATGGTCTTGACT 561 AGGACTTTTTAAATGAATGGTGTCTGCAGGTAGATGATCATGAAAATATCTCTAACAAAGTTTTACTCTTCTATGAAATG 641 CAGAATTTCTAGTACCTGCCTCCTTTGTTTTTGTAATAATTAAAATACTTCTTGTATAAAGAGATTAGTTCAGCCTGTTA 721 GTAAGTCTGCAGAGATGATGCTGAGTTGGTTGTGATTTTTAGAATAGACTCCTGGGTTGTTTTACAAATGTGCCATATTG 801 GCATGTCTTACAGTGATACCTCAAACACAGAAATTTTTATTTAGGAAGATAGCTAAATCTTTATTAGAACTGATTTTTAT 881 TGTATTCAGTATAAATTTTATGAAGCTTGTTTCTATGAGTACTGTGGAAAATTTTATAAATGTGAGCATATATATTTATT 961 TTGTCTGACATAATTTGTAGTTTTAAAGCAAGTTTCACACTGAACTTAACGTTTTCATAAATGACCAGTTTGGGATGTTT 1041 CTCTCTTTTACTTTAGTGGCAAACTCAAGAGTAAAAAGTGTCAAAAAAAGAATTGAGAATTTTATTCTGTACTTTTTAAA 1121 ATTTAAGAGCCAGGGAGTTGCATCATGAAAGCCTTTGTATAATAATGGAAATTTTATATGGGTAAGCATTTTCAAACACA 1201 TATTAGTAGATACGTTTTTTAAATTTCTATTTTCACATTGATCAGTGTTACTTTGCTTAATACTTAGGTAGCCCTTATGT 1281 CCACTAAAGTAAATGCTTATGTTGTAGAAGCATCGAACATCAACCAATGTCATGGCACAGCACCAAAGATTGCAAATACC 1361 TCACTATGGTGCGCTTAGAAATTTTCAAATTGATAACCTATAGATACGGCTGCAGGTGAATTCATGATAGTGAAATCAGC 1441 TAAGTATACTTAACCTCACAGGCTAGAAAGGTTTACTGATTCTTGTTTCACCTGGCACCCAATGTGGATACCCTCAGTAA 1521 GACTCAGGGAGCCTTATAACTCCTCTTAACATATGCTTACCCATGCTTAAATTCTAGGGAAGCTGTATCCACAGCCCTCT 1601 GCATTGCAGCCATGAGAGCTCTCACGCTTTCAACCCTTCCATAACCTAATTTAGTCATTTGGGCCTCTCAAAAGGAAATG 1681 CTTTTGTTTAAATAGGTCAGTCAGTTACTGGGAGAAAAAATACAGAGCCAGTAGGTTTTTAGGGATTTGTTTTGCCTTTG 1761 CTGCTAGTTTTTTGAAAATATTCTTCGATTATCAAGATTTTAAAAATCGGTTTTTAATATAAAGCTTTTTTAAAAACGAG 1841 GCTGGCACAAGTGCAGTGGTGTTTCTTTACTCCCACTGCTTGACTTGACTAGCCTTGAAAAAATAACAGTAAAATAAAAT 1921 ATTAAAAAATAATTAGAAAATGCTACAAAGGCAATGACCTTATTCCATTGAGTAAGATAGTTAAAAATGATAGTAATTGT 2001 AGTGAAATAGTTAATTACTTGTAAGTTTTATTACTGTTAATTGTAGAGATTATAAATTGGCTCATTAGGTTTCTGAATGG 2081 TGACACAATAATGACTGAGAAGAGCAAAAGTCAGTCCTCGTTAACTAATGTAGTATGCAAATTAAAATATTTTAATGATC 2161 AGTAATTTTCCCCCCAGAAATGATGTTGGCATTTCTAAGTAAATTTCCCATAATTTTAGCATAGTTTATGAAATTGAATA 2241 AAAATTTATTTTCACTGAAGTAATTTTCTTCTAATATGATATTATTATTGAGATTGGATGCAAATCTCATGAATATGTTT 2321 TAGAAGAAAATTAATGAAATTCCCTCCCAGGCAGTATGTACCAGAAGGAAAACTGAATTTAGCAGTAAAACAGTCCTGGT 2401 CATTCTAACTACCTGTATGATCTTGAACAAAGTCACTTAGTTTCCCTGGGCCTTGGTGTCTTTCGTCTATAAAATATTGT 2481 ACCAGATTATCTCTGAAATCACTTCAAGGTTTAATATATATAATTATCAATATTTTAAAATTCAAGCAATATTCACTTTA 2561 GAAATTATTATAACATTCTATAATAGTAAAGGTTGAATTTATTAATATAATAAACACGTTCAACTTCTTCAAGCAGATAA 2641 TTGATATTTGGTTCATATTCTTACAACCTAATGCATGTCATTTTCACCAAATGCAGGCAGAATTTATATTTAGGTTTGCA 2721 TCTGGAACTAGATTATCTGGCACTTTATGGCCATTATTTTTGGGTTGATGGACCTTCTCACCACACAATTTCCCCCTTTT 2801 TTTTTTTTGCATATCATATGTTGGTTGATATTTCTCAGAGGTATCCCTATTTCTTCATACTTAATATACATCTCCATTTA 2881 CATCTTTGACTCTCTGAGGTCAAAACAACAATAAATGAGAAGTAAAACAACTATATGTGTTTGTATTTACAACTGTATCT 2961 AAAATTATATAACCCTAGTTTACCTTCAGAGTAAACTAGGCTGAAGAGTTGTTAATAATGTTGATAAAAATGCCATTGAA 3041 TCCTTTCTTCAACAAATATTTATTGAGTACCTAACGTGGCAAACGCTGTGCTAAGTACTGGGGATACAGAGATAAGTAAG 3121 ACACATTTGCCTCCCTGAAGGACTTCACAGTGTAGTTGGTAGGAGAAACACCAGAGCATACACCGTTATATAATTAGTGC 3201 AGTAATTGACATGAACATGAGTTTATAGAAACTCGGGGTTACCTAAAGTAGTCTGGATAAATTAGAAGAGGCTACCTAGA 3281 GAAAGTAGTGACTGAATTGCAATTTGATTAAGGATAAGAATGAGGGTTATGGCAGTTCCTGACAGAGTGGGTACTGTGAA 3361 CAAACACCAGAGGTAGAACAAGCTGTGTTATGTGTTTGTCAAGAATTACAAGCAATCTGGTGTTGCTGGTGTATCATAGG 3441 CGAGGCAGGAAGTGGTAAGAATTGAGACTACCATTTTAAGTTCTTAGGAACAGGAGGAAGGAGTCGTGTGTTCCGTGTTT 3521 GGGAGCTTGAACTGTAATGTGTAAGCAATGAGACACCATTAAAGAGTTTCAAGGGGGGCCGGGCACAGTGGCTCACGCCT 3601 GTAATCCCAGCACTTTGGGAGGCTGAGGCGGGCGGATCACCTGAGGTCAGGAGTTCAAGACCAGCCTGGCCAACTTGGCG 3681 AAACCCTGTCTCTACTAAAAATAGAAAAATTAGCCGGACGTGGTGACAGGCACCTGTATTCCCAGCTACTCTGGAGTCTG 3761 GGGCAGGAGAATCGCTCAAACCCAGGAGGTGGAAGTTGCAGTAAGCTGAGATCACACCACTGTACTCCAGCCTGGGCGAC 3841 AGAGCGAGACTCTATCTCAAAAAAAAAAAAAGATTTTAAGGAAGGAAATGACTTTTATTAGGGTTTGGTTTTATCAATTT 3921 CATAATCCGATTAATCCCACCATTTTTAAAAGATGAAATTGCTTTCATTAGAAGGCTACATAAAATATAATTTGATTATT 4001 TTAGGCTCTATTATTAGACTCACATTTCTTTCTACAGTCTCATTATTATTTCCAAAAATTACACAGTAACCTAAATCATC 4081 TAAAAACACATAAAGCTACTGTATTCTTTATTAGATCCATCCCCAGAGTTATATGTACATGTACATACTTTGAGATGTGT 4161 TTTGTTCTTAATTGTATTTTAGGTTATTTTTGACTGACTTAAATTCTATCACTATTTTAATATTTGTTAGGTCCGAATAA 4241 ACCATTTAGAATATTTTTCAGTGTACAAAATGTGCTGTAATTTAATAAGGCCCCTTGCTTTTAAAATTTGGCTTAACCTG 4321 TGAAGCACAACTGCTTCAGAGTTACAGAGAAACATACCAGTTGGTCCACTGGATGAGCCCTGTGGTTCTACCTCAGGTAA 4401 CCTAGTGATAAGCTAGCTCAGCAGGGAGTGCTTCAAGGACTCCAGCTGATCCTAGTGCTGAGACCAAAACTTCCTGGACA 4481 TTGGGTGCCCAAGAACAGTAGGTTTCTTATACCAGTGTGACAATAATCCCAGTTGCGAAGGCCAGTCTTCTGATCTCAGT 4561 ATCTCCTCCCAACTCCTCTAAAAATAGGTAGAGTGGCAGAGAATTGGGGTGCCTCTTCTATAGCACAACCCATGATGCAT 4641 CCAGTCATGCCTGACCCCACTATGCCTTTCCCACAAATTGGGAGGAGTTGGGGCAGTGAGCATTTTGCTAGCTCTGTCTG 4721 TTTCTTGCTTCTTGTGCCATTTATAGTCCTTGGCCATGAGCAACAAAAGTAGAATGGTGCCAGTGCCTTAACTAAATTTT 4801 TCTCAACCTAGATTTTCACCTGAGACAATATGGTAATATTATTAAATTACTGTAAAGATAGCAAATTTTCTGGGATACTT 4881 TAAAATCAAAGTTGTATCAAAGATCAAGAAGCACCCATAAAAGCTTTATAAACTTTCACAAAAAATAAGTGAAAATTCTT 4961 TGTTTTTATGGCCGTGTAAAATGTCATTTTTATAATGGAAATGTCTTAATTTTCAAACTTAACATATACTTTAAGCAATT 5041 TTAGTATTTAAACCTTTGCAAAATTGTATTTTTGAATGTGAAGTTCAACTTTGGCAGTAGGTTGTTGCAATAGTGATCTG 5121 GCACTATGGTGCCAGTATAGCCACATAGGGTTATTTAAATTAATTAAATAAATGAAAAATTTTATTTTTTCAGTTGCATT 5201 AGCCACATCTTAAGTGTTCAGTAGCCACATGTGACTGGTGGCTACCATATTAGTGCAGATATAGAAAGAACATTTCCATC 5281 ATCACAGAAACTTCTCTTAATTCTGGTCTAGAAGATAACCTTAGTACTTGGTAGAAATTTTGACAGGCTAATGACGAAAA 5361 GTTTGTAACCCTGAGCTTTGCATGCCCAAGAAAAATAAGGTATTCTTTTTTATATATCAGACCAGAGAAGCTGTATTCAG 5441 CACATTTTGAAATGCTAGTTTTTGGCTATGGCCATACCACCCTAAATGTGCCAGATCTTGTCTGAAATGCTAGTTTCTGA 5521 CTACAAAAACTACAGGACATAGTAGATATGCTCAGTAGAGCTGCTTAAAATAATTCCCTTTTTTTTTCTGTTGAATTCTG 5601 TTACAAAACCAGGTCTGTGTTATAATAGAAAACACACTTATGAATAAAAATCTTTAAAAATTATAATTTGCAGAAATTAG 5681 TTTTATTTCTAGATTTCTAGGTGGTATTAATGTGATAGCATTAGGTGGGACCAGAGAACTCATTTGTTTTGTAGCTTTCA 5761 TTATACAGATTATTTAGGAAATATATCAGCAAAGGATTTTTTGTTATGCTTATCTCTTGAAACAAAATATTTATTGTACA 5841 GATTATACATTGTGATTTTTTTGTTACTGAGTATATTGTTTGTGCCCAGAAAAATCTAAAAAGATGTGGGTTGACTTCTA 5921 AGAGATTTAAGAACAAGTCACCTCTAGTTTTTAAGACAGTTCCCTTGATATTTACCTATCCAGTACCATCTCATAAGAAT 6001 AACTGCCTGTAAGTATCAGAAAGTTGAGAAATGCTGGTAATGTGACATAAACTTCTCACTGTTCTTCACTGAGATAGGAC 6081 TGCTTATCTTGTTATTGATAAATTATTTAATTTCTCCTGAATAATTAGCATAATCTCATGTGATACAGAAACATCTTAAT 6161 TAGCAAATAAATTTATACAAAGGAAAACCAATAAAACCTTAATGTGCGTTTAATAAAGTAACTGAATGATCAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545212. RNA binding protein: AGO1. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 285672.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Disease | 285672.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in GSM1065667. RNA binding protein: AGO1. Condition:4-thiouridine
"PAR-CLIP data was present in GSM1065668. RNA binding protein: AGO1. Condition:4-thiouridine
"PAR-CLIP data was present in GSM1065669. RNA binding protein: AGO1. Condition:4-thiouridine
... - Memczak S; Jens M; Elefsinioti A; Torti F; et al., 2013, Nature. |
Article |
- Memczak S; Jens M; Elefsinioti A; Torti F; et al. - Nature, 2013
Circular RNAs (circRNAs) in animals are an enigmatic class of RNA with unknown function. To explore circRNAs systematically, we sequenced and computationally analysed human, mouse and nematode RNA. We detected thousands of well-expressed, stable circRNAs, often showing tissue/developmental-stage-specific expression. Sequence analysis indicated important regulatory functions for circRNAs. We found that a human circRNA, antisense to the cerebellar degeneration-related protein 1 transcript (CDR1as), is densely bound by microRNA (miRNA) effector complexes and harbours 63 conserved binding sites for the ancient miRNA miR-7. Further analyses indicated that CDR1as functions to bind miR-7 in neuronal tissues. Human CDR1as expression in zebrafish impaired midbrain development, similar to knocking down miR-7, suggesting that CDR1as is a miRNA antagonist with a miRNA-binding capacity ten times higher than any other known transcript. Together, our data provide evidence that circRNAs form a large class of post-transcriptional regulators. Numerous circRNAs form by head-to-tail splicing of exons, suggesting previously unrecognized regulatory potential of coding sequences.
LinkOut: [PMID: 23446348]
|
CLIP-seq Support 1 for dataset GSM4903833 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_a |
Location of target site | NM_173829 | 3UTR | CCAAGAAAAAUAAGGUAUUCUUUUUUAUAUAUCAGACCAGAGAAGCUGUAUUCAGCACAUUUUGAAAUGCUAGUUUUUGGCUAUGGCCAUACCACCCUAAAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM4903834 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_b |
Location of target site | NM_173829 | 3UTR | AGAGAAGCUGUAUUCAGCACAUUUUGAAAUGCUAGUUUUUGGCUAUGGCCAUACCACCCUAAAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM4903835 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_c |
Location of target site | NM_173829 | 3UTR | UCAGACCAGAGAAGCUGUAUUCAGCACAUUUUGAAAUGCUAGUUUUUGGCUAUGGCCAUACCACCCUAAAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM4903836 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_a |
Location of target site | NM_173829 | 3UTR | UCAGACCAGAGAAGCUGUAUUCAGCACAUUUUGAAAUGCUAGUUUUUGGCUAUGGCCAUACCACCCUAAAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM4903838 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_c |
Location of target site | NM_173829 | 3UTR | AGUUUUUGGCUAUGGC |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset GSM545212 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000513458.4 | 3UTR | GGCCAUACCACCCUAAAUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 7 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000513458.4 | 3UTR | GGCUAUGGCCAUACCACCCUAAAUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
CLIP-seq Support 8 for dataset GSM1065667 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_6 |
Location of target site | ENST00000513458.4 | 3UTR | GGCUAUGGCCAUACCACCCUAAAUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 9 for dataset GSM1065668 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_7 |
Location of target site | ENST00000513458.4 | 3UTR | GCUAUGGCCAUACCACCCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
CLIP-seq Support 10 for dataset GSM1065669 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / 4-thiouridine, ML_MM_8 |
Location of target site | ENST00000513458.4 | 3UTR | GGCUAUGGCCAUACCACCCUAAAUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23446348 / GSE43573 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
53 hsa-miR-103b Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT218386 | E2F3 | E2F transcription factor 3 | 2 | 2 | ||||||||
MIRT404221 | RPL7L1 | ribosomal protein L7 like 1 | 2 | 2 | ||||||||
MIRT441502 | SPG20 | spartin | 2 | 6 | ||||||||
MIRT444124 | ZNRF3 | zinc and ring finger 3 | 2 | 2 | ||||||||
MIRT454236 | OSBPL10 | oxysterol binding protein like 10 | 2 | 4 | ||||||||
MIRT457919 | ZNF212 | zinc finger protein 212 | 2 | 2 | ||||||||
MIRT462254 | LAMA4 | laminin subunit alpha 4 | 2 | 2 | ||||||||
MIRT463176 | ZNF281 | zinc finger protein 281 | 2 | 2 | ||||||||
MIRT472355 | TSPAN1 | tetraspanin 1 | 2 | 2 | ||||||||
MIRT474133 | LIN54 | lin-54 DREAM MuvB core complex component | 2 | 4 | ||||||||
MIRT494946 | IFFO2 | intermediate filament family orphan 2 | 2 | 2 | ||||||||
MIRT497403 | NPY4R | neuropeptide Y receptor Y4 | 2 | 2 | ||||||||
MIRT497641 | GLDN | gliomedin | 2 | 2 | ||||||||
MIRT505340 | TMEM245 | transmembrane protein 245 | 2 | 6 | ||||||||
MIRT505680 | SESTD1 | SEC14 and spectrin domain containing 1 | 2 | 6 | ||||||||
MIRT510706 | SREK1IP1 | SREK1 interacting protein 1 | 2 | 6 | ||||||||
MIRT512198 | C1orf43 | chromosome 1 open reading frame 43 | 2 | 2 | ||||||||
MIRT522089 | NUFIP2 | NUFIP2, FMR1 interacting protein 2 | 2 | 4 | ||||||||
MIRT525074 | FRK | fyn related Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT531276 | PPIL3 | peptidylprolyl isomerase like 3 | 2 | 2 | ||||||||
MIRT535119 | PLXNA2 | plexin A2 | 2 | 2 | ||||||||
MIRT540836 | GNAT1 | G protein subunit alpha transducin 1 | 2 | 4 | ||||||||
MIRT541018 | WIPI2 | WD repeat domain, phosphoinositide interacting 2 | 2 | 2 | ||||||||
MIRT545752 | CA12 | carbonic anhydrase 12 | 2 | 4 | ||||||||
MIRT546404 | SRP9 | signal recognition particle 9 | 2 | 2 | ||||||||
MIRT547991 | HCFC2 | host cell factor C2 | 2 | 4 | ||||||||
MIRT554502 | SAE1 | SUMO1 activating enzyme subunit 1 | 2 | 2 | ||||||||
MIRT558360 | DMTF1 | cyclin D binding myb like transcription factor 1 | 2 | 2 | ||||||||
MIRT558863 | CD2AP | CD2 associated protein | 2 | 2 | ||||||||
MIRT559939 | ZNF567 | zinc finger protein 567 | 2 | 2 | ||||||||
MIRT566300 | PPM1A | protein phosphatase, Mg2+/Mn2+ dependent 1A | 2 | 2 | ||||||||
MIRT567490 | FOXK1 | forkhead box K1 | 2 | 2 | ||||||||
MIRT617139 | ZNF556 | zinc finger protein 556 | 2 | 2 | ||||||||
MIRT625400 | AKR7L | aldo-keto reductase family 7 like (gene/pseudogene) | 2 | 2 | ||||||||
MIRT626491 | CEP89 | centrosomal protein 89 | 2 | 2 | ||||||||
MIRT629487 | GSN | gelsolin | 2 | 4 | ||||||||
MIRT638456 | PLXDC2 | plexin domain containing 2 | 2 | 2 | ||||||||
MIRT648498 | CMBL | carboxymethylenebutenolidase homolog | 2 | 2 | ||||||||
MIRT654845 | PPM1L | protein phosphatase, Mg2+/Mn2+ dependent 1L | 2 | 2 | ||||||||
MIRT664587 | HSD17B12 | hydroxysteroid 17-beta dehydrogenase 12 | 2 | 2 | ||||||||
MIRT664977 | TDRD1 | tudor domain containing 1 | 2 | 2 | ||||||||
MIRT665028 | ELK1 | ELK1, ETS transcription factor | 2 | 2 | ||||||||
MIRT666043 | STON2 | stonin 2 | 2 | 2 | ||||||||
MIRT668863 | CRY2 | cryptochrome circadian clock 2 | 2 | 2 | ||||||||
MIRT669297 | C17orf85 | nuclear cap binding subunit 3 | 2 | 2 | ||||||||
MIRT680975 | DCAF17 | DDB1 and CUL4 associated factor 17 | 2 | 2 | ||||||||
MIRT682267 | RS1 | retinoschisin 1 | 2 | 2 | ||||||||
MIRT685283 | KIAA1143 | KIAA1143 | 2 | 2 | ||||||||
MIRT693375 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 | 2 | ||||||||
MIRT701785 | MSL1 | male specific lethal 1 homolog | 2 | 2 | ||||||||
MIRT709373 | SPECC1 | sperm antigen with calponin homology and coiled-coil domains 1 | 2 | 2 | ||||||||
MIRT715154 | IL12B | interleukin 12B | 2 | 2 | ||||||||
MIRT734499 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 3 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|